Brand semaglutide
Sold by ElixaMD · Injection · device not recorded · every brand semaglutide record
The program identifies an injection, but the delivery device has not been established.
Price
No comparable monthly price verified at this reading. See dated notes for any advertised starting figures.
We earn nothing from this link. It opens ElixaMD's website without a paid referral.
History
Fewer than two comparable calendar-month readings are available for a price trend. Day- or week-based supplies, introductory offers and unverified payment terms are not connected in this chart.
- October 2026 — Entry added to the register
Sourcing and terms
| Pharmacy | Triad Rx, RedRock and Beaker (listed partner network; individual assignment unconfirmed) |
|---|---|
| States | Not disclosed |
| Prescriber | Both |
| Cancellation | Request cancellation by emailing help@elixamd.com or using patient-portal chat at least 72 hours before the next billing date; a late request may take effect the following cycle. The policy lists a first-72-hours refund only if no subscription services were received, medical-disqualification refunds, and refunds for unshipped months on multi-month billing, then includes a blanket exclusion except medical disqualification. Monthly cancellation does not generally refund the current or prior paid month. Terms also make completed consultations nonrefundable and prescription sales final. These differing clauses are preserved; confirm the applicable refund rather than assuming a money-back guarantee. https://elixamd.com/cancellation-and-refund-policy https://elixamd.com/terms-and-conditions |
| Membership | Required. $99 over an unstated period. The Wegovy injection card lists a $99 membership plus medication cost without a billing interval. |
| Consult fee | Not disclosed |
Recorded from elixamd.com. Unlike the price rows above, these carry a summary rather than a word-for-word quotation, so they are not shown in quotation marks.
Notes
- 1. October 2026 — Wegovy injection is listed separately from the compounded program. Its $99 membership is a care fee; the medication price and membership billing interval are unconfirmed. https://glp1.elixamd.com/
- 2. October 2026 — The provider describes cash-pay prescriptions, with possible insurance reimbursement for brand options. The consultation process includes OpenLoop clinician contact after checkout; refund terms also describe live and electronic reviews. https://elixamd.com/cancellation-and-refund-policy
- 3. October 2026 — The Wegovy injection card still advertises $99 Membership + Medication Cost. This is a care-membership amount, not the medication price or an established all-in bill; the card does not specify its billing interval. Generic statements that medication is included in the default program do not override the separately itemized branded offer. https://glp1.elixamd.com/
- 4. October 2026 — Triad Rx, RedRock Pharmacy and Beaker Pharmacy & Compounding are named as partner pharmacies. No individual assignment is established. OpenLoop is the clinical-provider network, not the dispensing pharmacy. A state-by-state GLP-1 availability list, exact dispensed device and any patient-specific prescription remain unconfirmed in the public pages. https://glp1.elixamd.com/
- 5. October 2026 — Cancellation requires at least 72 hours before renewal, while the separate first-72-hours refund exception requires that no subscription services have been received. These are different conditions. The policy also describes medical disqualification and unshipped multi-month refunds before its broader nonrefund clause; the general terms separately make completed consultations nonrefundable and prescription sales final. No universal refund promise is inferred. https://elixamd.com/cancellation-and-refund-policy https://elixamd.com/terms-and-conditions
7 further notes concern other ElixaMD programs and sit on the provider record.
Treatment Registry is an independent editorial record. It is not a government registry, a licensing body, or a certification. An entry means we recorded what a company published on a given date. It does not mean we recommend the program, and it does not mean the program is approved by anyone.